Hansa Biopharma AB provided preliminary unaudited revenue guidance for the first quarter ending March 31, 2024. for the quarter, the company expects to report revenue of approximately SEK 54 million, an increase of 10% versus the prior quarter and a 234% increase against a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29 SEK | +6.15% | +3.06% | +10.69% |
Apr. 18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
Apr. 18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.69% | 137M | |
+2.20% | 42.75B | |
+47.70% | 41.61B | |
+12.30% | 41.34B | |
-8.83% | 26.59B | |
+6.58% | 25.49B | |
-22.91% | 18.12B | |
+30.28% | 12.24B | |
-2.05% | 11.76B | |
+8.99% | 11B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma AB Provides Preliminary Unaudited Revenue Guidance for the First Quarter Ending March 31, 2024